DK2002258T3 - Anvendelse af gelsolin til behandling af multipel sklerose og diagnosticering af neurologiske sygdomme - Google Patents

Anvendelse af gelsolin til behandling af multipel sklerose og diagnosticering af neurologiske sygdomme Download PDF

Info

Publication number
DK2002258T3
DK2002258T3 DK07753226.5T DK07753226T DK2002258T3 DK 2002258 T3 DK2002258 T3 DK 2002258T3 DK 07753226 T DK07753226 T DK 07753226T DK 2002258 T3 DK2002258 T3 DK 2002258T3
Authority
DK
Denmark
Prior art keywords
gelsolin
subject
multiple sclerosis
level
treating
Prior art date
Application number
DK07753226.5T
Other languages
English (en)
Inventor
Thomas P Stossel
Bonnie Dittel
Katarzyna Maresz
Po-Shun Lee
Original Assignee
Brigham & Womens Hospital Inc
Bloodcenter Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital Inc, Bloodcenter Res Foundation Inc filed Critical Brigham & Womens Hospital Inc
Application granted granted Critical
Publication of DK2002258T3 publication Critical patent/DK2002258T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Claims (10)

1. Gelsolin til anvendelse ved en fremgangsmåde til behandling af et individ, som har multipel sklerose, hvilken fremgangsmåde omfatter administration af gelsolin til individet flere gange.
2. Gelsolin til anvendelse ved en fremgangsmåde til behandling af et individ, som har multipel sklerose, ifølge krav 1, hvor individet ellers er fri for indikationer, der nødvendiggør behandling med gelsolin.
3. Gelsolin til anvendelse ved en fremgangsmåde til behandling af et individ, som har multipel sklerose, ifølge krav 1, hvor fremgangsmåden endvidere omfatter administration af et andet middel til behandling af multipel sklerose.
4. Gelsolin til anvendelse ved en fremgangsmåde til behandling af et individ, som har multipel sklerose, ifølge krav 3, hvor det andet middel er interferon (IFN)^lb (Betaseron eller Betaferon), IFN-pia (Avonex, Rebif), glatirameracetat (Copaxone), mitoxantron (Novantrone), azathioprin, cyclosporin, methotrexat, cyclophosphamid, intravenøst immunglobulin, prednison, methylprednison, prednisolon, methylprednisolon, dexamethason, adrenocorticotropt hormon (ACTH), corticotropin, 2-chlordeoxyadenosin (2-CDA, cladribin), inosin, interleukin-2-antistof (Zenapax, daclizumab), leucovorin, teriflunomid, estroprogestiner, desogestrel, etinilestradiol, BHT-3009, ABT-874, (Bacille Calmette-Guérin)-vaccine (BCG-vaccine), T-cellevaccination, CNTO 1275, Rituximab, Tysabri (natalizumab), N-acetylcystein, minocyclin, R00506997 eller et statin.
5. Gelsolin til anvendelse ved en fremgangsmåde til behandling af et individ, som har multipel sklerose, ifølge krav 1, hvor fremgangsmåden endvidere omfatter udvælgelse af et individ på det grundlag, at individet vides at have et niveau af gelsolin, som er mindst 10% mindre end det målte gennemsnitsniveau for en tilsyneladende rask population af individer; og administration af gelsolin til individet i en til behandling af individet, som har multipel sklerose, effektiv mængde.
6. Gelsolin til anvendelse ved en fremgangsmåde til behandling af et individ, som har multipel sklerose, ifølge krav 5 i kombination med et andet middel til behandling af multipel sklerose.
7. Gelsolin til anvendelse ved en fremgangsmåde til behandling af et individ, som har multipel sklerose, hvilken fremgangsmåde omfatter: (i) behandling af individet med en første behandling til behandling af multipel sklerose, (ii) opnåelse af et niveau af gelsolin hos individet, (iii) sammenligning af det i (ii) opnåede niveau af gelsolin med en forudbestemt værdi svarende til et forudbestemt niveau af gelsolin hos en tilsyneladende rask kontrolpopulation, og, hvis det forudbestemte niveau af gelsolin ikke er nået, (iv) behandling af individet med et andet middel til behandling af multipel sklerose, og gentagelse af (ii) og (iii), indtil det forudbestemte niveau af gelsolin er nået.
8. Fremgangsmåde til evaluering af virkningen af en behandling til behandling af eller reduktion af risikoen for multipel sklerose hos et individ, hvilken fremgangsmåde omfatter: (i) opnåelse in vitro af et niveau af gelsolin i blod, plasma eller serum fra et individ, som gennemgår behandling med et middel til behandling af multipel sklerose, (ii) sammenligning af det i (i) opnåede niveau af gelsolin med en forudbestemt værdi svarende til et forudbestemt niveau af gelsolin hos en tilsyneladende rask kontrolpopulation og (iii) bestemmelse af, om niveauet af gelsolin i (i) er på eller over det forudbestemte niveau, hvilken bestemmelse er indikativ for, om behandlingen er virkningsfuld.
9. Fremgangsmåde ifølge krav 8, hvor trin (i) og trin (ii) og/eller trin (iii) gentages for at monitorere individets niveauer af gelsolin over tid.
10. Fremgangsmåde ifølge krav 8, hvor midlet er gelsolin, interferon (IFN)-pib (Betaseron eller Betaferon), IFN-pia (Avonex, Rebif), glatirameracetat (Copaxone), mitoxantron (Novantrone), azathioprin, cyclosporin, methotrexat, cyclophosphamid, intravenøst immunglobulin, prednison, methylprednison, prednisolon, methylprednisolon, dexamethason, adrenocorticotropt hormon (ACTH), corticotropin, 2-chlordeoxyadenosin (2-CDA, cladribin), inosin, interleukin-2-antistof (Zenapax, daclizumab), leucovorin, teriflunomid, estroprogestiner, desogestrel, etinilestradiol, BHT-3009, ABT-874, (Bacille Calmette-Guérin)-vaccine (BCG-vaccine), T-cellevaccination, CNTO 1275, Rituximab, Tysabri (natalizumab), N-acetylcystein, minocyclin, R00506997 eller et statin.
DK07753226.5T 2006-03-15 2007-03-14 Anvendelse af gelsolin til behandling af multipel sklerose og diagnosticering af neurologiske sygdomme DK2002258T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78250906P 2006-03-15 2006-03-15
PCT/US2007/006581 WO2007106577A2 (en) 2006-03-15 2007-03-14 Gelsolin in the treatment and diagnosis of neurological disease

Publications (1)

Publication Number Publication Date
DK2002258T3 true DK2002258T3 (da) 2018-01-02

Family

ID=38510104

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07753226.5T DK2002258T3 (da) 2006-03-15 2007-03-14 Anvendelse af gelsolin til behandling af multipel sklerose og diagnosticering af neurologiske sygdomme

Country Status (11)

Country Link
US (2) US8440622B2 (da)
EP (1) EP2002258B1 (da)
JP (2) JP2009530613A (da)
CN (1) CN101460843B (da)
CA (1) CA2680333C (da)
DK (1) DK2002258T3 (da)
ES (1) ES2651619T3 (da)
HU (1) HUE035980T2 (da)
PL (1) PL2002258T3 (da)
PT (1) PT2002258T (da)
WO (1) WO2007106577A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2848385T3 (es) * 2003-11-12 2021-08-09 Univ Pennsylvania Métodos de uso de gelsolina para tratar o prevenir septicemia bacteriana
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
DK1755661T3 (da) * 2004-05-12 2014-06-16 Brigham & Womens Hospital Gelsolin til anvendelse til behandling af infektioner
JP4348631B2 (ja) * 2005-03-29 2009-10-21 セイコーエプソン株式会社 半導体素子の製造方法
KR101556790B1 (ko) 2006-03-15 2015-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. 염증성 질환의 진단 및 치료를 위한 겔솔린의 용도
EP2708603B1 (en) 2008-01-25 2017-04-19 The General Hospital Corporation Diagnostic and therapeutic uses of gelsolin in renal failure
WO2009124226A2 (en) * 2008-04-03 2009-10-08 The Trustees Of The University Of Pennsylvania Gelsolin uses in neurological disorders
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
DE102010026500A1 (de) * 2010-07-07 2012-01-12 Arthrogen Gmbh Verfahren zur Herstellung von autologen Proteinen
EP2653476B1 (en) * 2010-12-16 2017-04-26 National Institute of Advanced Industrial Science And Technology Method for enrichment and separation of spinal fluid glycoprotein, method for searching for marker for central nervous system diseases which utilizes the aforementioned method, and marker for central nervous system diseases
KR101416954B1 (ko) 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
US10161006B2 (en) 2014-03-11 2018-12-25 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Diagnosis of hematologic diseases
FR3036188B1 (fr) * 2015-05-12 2019-06-07 Biomerieux Prediction du risque de developper, pour des patients admis en service de reanimation, une infection disseminee
JP6947449B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
SI3506921T1 (sl) 2016-08-31 2023-10-30 Mapi Pharma Ltd. Depojski sistemi, ki vsebujejo glatiramer acetat
JP7602322B2 (ja) 2017-03-26 2024-12-18 マピ ファーマ リミテッド 進行型の多発性硬化症を治療するためのグラチラマーデポシステム
WO2019173258A1 (en) * 2018-03-05 2019-09-12 Academia Sinica Methods and kits for diagnosing and/or treating peripheral neuropathy
EP3990440A4 (en) * 2019-06-28 2022-09-07 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF DISEASES OF THE NEUROMYELITIS OPTICA SPECTRUM
WO2022067319A1 (en) * 2020-09-23 2022-03-31 Bioaegis Therapeutics Inc. Compositions and methods for identifying and treating microparticle-associated diseases and conditions
CN116615216A (zh) * 2020-09-23 2023-08-18 生物保护医疗公司 用于鉴定和治疗微粒相关疾病和病症的组合物和方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US627353A (en) * 1899-06-20 Cis robinson
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
CA2016227A1 (en) 1989-05-18 1990-11-18 Xandra O. Breakefield Genetic diagnosis of torsion dystonia
ATE171625T1 (de) 1990-04-11 1998-10-15 Brigham & Womens Hospital Therapeutische verwendung von actin-bindenden verbindungen
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
WO1991017170A1 (en) 1990-05-04 1991-11-14 Biogen, Inc. Multimeric gelsolin fusion constructs
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5360350A (en) 1991-08-23 1994-11-01 The Whitaker Corporation Sealant compositions and sealed electrical connectors
US5691160A (en) 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5804427A (en) 1995-05-19 1998-09-08 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US5925529A (en) 1995-06-07 1999-07-20 The Regents Of The University Of California Method for discovery of peptide agonists
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
WO1998024465A1 (en) 1996-12-04 1998-06-11 The Victoria University Of Manchester Wound healing and treatment of fibrosis
EP2305236A1 (en) 1997-04-02 2011-04-06 The Brigham And Women's Hospital, Inc. Means of Ascertaining an Individual's Risk Profile for Atherosclerotic Disease
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6409599B1 (en) 1999-07-19 2002-06-25 Ham On Rye Technologies, Inc. Interactive virtual reality performance theater entertainment system
AU2002225219A1 (en) 2001-01-26 2002-08-06 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis
EP1249244A1 (en) 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
US20060089310A1 (en) 2002-02-06 2006-04-27 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
AU2003226401A1 (en) 2002-04-16 2003-11-03 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
WO2004001421A2 (en) 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
WO2004082617A2 (en) 2003-03-14 2004-09-30 Ppd Biomarker Discovery Sciences, Llc Biological markers for diagnosing rheumatoid arthritis
ES2848385T3 (es) 2003-11-12 2021-08-09 Univ Pennsylvania Métodos de uso de gelsolina para tratar o prevenir septicemia bacteriana
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
DK1755661T3 (da) 2004-05-12 2014-06-16 Brigham & Womens Hospital Gelsolin til anvendelse til behandling af infektioner
BRPI0510915A (pt) * 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
WO2007041245A2 (en) 2005-09-29 2007-04-12 Biogen Idec Ma Inc. Biomarkers for multiple sclerosis and methods of use thereof
KR101556790B1 (ko) 2006-03-15 2015-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. 염증성 질환의 진단 및 치료를 위한 겔솔린의 용도
EP2708603B1 (en) 2008-01-25 2017-04-19 The General Hospital Corporation Diagnostic and therapeutic uses of gelsolin in renal failure

Also Published As

Publication number Publication date
US20130230455A1 (en) 2013-09-05
JP6203995B2 (ja) 2017-09-27
CA2680333A1 (en) 2007-09-20
ES2651619T3 (es) 2018-01-29
EP2002258A2 (en) 2008-12-17
EP2002258A4 (en) 2009-03-18
WO2007106577A2 (en) 2007-09-20
CN101460843B (zh) 2018-06-22
US8440622B2 (en) 2013-05-14
HUE035980T2 (hu) 2018-06-28
PL2002258T3 (pl) 2018-06-29
CN101460843A (zh) 2009-06-17
EP2002258B1 (en) 2017-09-27
JP2012053071A (ja) 2012-03-15
US20100021428A1 (en) 2010-01-28
PT2002258T (pt) 2017-12-18
CA2680333C (en) 2016-10-25
JP2009530613A (ja) 2009-08-27
WO2007106577A3 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
DK2002258T3 (da) Anvendelse af gelsolin til behandling af multipel sklerose og diagnosticering af neurologiske sygdomme
EP2001496B1 (en) Use of gelsolin to diagnose and treat inflammatory diseases
WO2016033187A1 (en) Use of gelsolin in the treatment and diagnosis of sickle cell disease
HK1124664B (en) Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
HK1124664A (en) Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
AU2013202205B2 (en) Use of Gelsolin to Diagnose and Treat Inflammatory Disease
HK1250781B (en) Use of gelsolin to diagnose and treat inflammatory diseases
HK1127121B (en) Use of gelsolin to diagnose and treat inflammatory diseases
HK1127121A (en) Use of gelsolin to diagnose and treat inflammatory diseases